Tianjin Chase Sun PharmaceuticalLtd (SZSE:300026) stock falls 6.2% in past week as three-year earnings and shareholder returns continue downward trend

For many investors, the main point of stock picking is to generate higher returns than the overall market. But if you try your hand at stock picking, you risk returning less than the market. We regret to report that long term Tianjin Chase Sun Pharmaceutical Co.,Ltd (SZSE:300026) shareholders have had that experience, with the share price dropping 44% in three years, versus a market decline of about 9.6%. The falls have accelerated recently, with the share price down 14% in the last three months.

With the stock having lost 6.2% in the past week, it's worth taking a look at business performance and seeing if there's any red flags.

View our latest analysis for Tianjin Chase Sun PharmaceuticalLtd

While markets are a powerful pricing mechanism, share prices reflect investor sentiment, not just underlying business performance. By comparing earnings per share (EPS) and share price changes over time, we can get a feel for how investor attitudes to a company have morphed over time.

Tianjin Chase Sun PharmaceuticalLtd saw its EPS decline at a compound rate of 35% per year, over the last three years. In comparison the 17% compound annual share price decline isn't as bad as the EPS drop-off. This suggests that the market retains some optimism around long term earnings stability, despite past EPS declines. With a P/E ratio of 63.05, it's fair to say the market sees a brighter future for the business.

The graphic below depicts how EPS has changed over time (unveil the exact values by clicking on the image).

Dive deeper into Tianjin Chase Sun PharmaceuticalLtd's key metrics by checking this interactive graph of Tianjin Chase Sun PharmaceuticalLtd's earnings, revenue and cash flow.

A Different Perspective

While the broader market gained around 14% in the last year, Tianjin Chase Sun PharmaceuticalLtd shareholders lost 8.4% (even including dividends). Even the share prices of good stocks drop sometimes, but we want to see improvements in the fundamental metrics of a business, before getting too interested. Unfortunately, last year's performance may indicate unresolved challenges, given that it was worse than the annualised loss of 3% over the last half decade. We realise that Baron Rothschild has said investors should "buy when there is blood on the streets", but we caution that investors should first be sure they are buying a high quality business. While it is well worth considering the different impacts that market conditions can have on the share price, there are other factors that are even more important. For instance, we've identified 3 warning signs for Tianjin Chase Sun PharmaceuticalLtd that you should be aware of.

For those who like to find winning investments this free list of undervalued companies with recent insider purchasing, could be just the ticket.

Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on Chinese exchanges.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.